Anxiety and depression in COVID-19: Treatment options [Расстройства тревожно-депрессивного спектра на фоне COVID-19: возможности терапии]

During the examination of post-COVID patients, a direct and indirect negative effect of COVID-19 on the nervous system is found. Among the mediated subjectively significant stress factors of the pandemic, a potential long-term threat to life, prolonged quarantine measures with self-isolation, lack of stable immunity, restriction of access to medical services, etc. are of particular importance. An increased frequency of depression (up to 53.5%), anxiety (up to 50.9%), and mixed anxiety/depressive disorders were reported during the pandemic. Psychopharmacotherapy in patients with COVID-19 should include drugs not only with minimally expressed undesirable effects and adverse drug interactions but also with the presence of additional therapeutic procognitive and somatotropic properties, similar to those identified in the antidepressant fluvoxamine. © 2021 Ima-Press Publishing House. All rights reserved.